Pharmacological inhibition of TLR9 activation blocks autoantibody production in human B cells from SLE patients

Federica Capolunghi, Maria M. Rosado, Simona Cascioli, Elia Girolami, Silvia Bordasco, Marina Vivarelli, Barbara Ruggiero, Elisabetta Cortis, Antonella Insalaco, Nicola Fantò, Grazia Gallo, Eleonora Nucera, Maria Loiarro, Claudio Sette, Rita De santis, Rita Carsetti, Vito Ruggiero

Research output: Contribution to journalArticle

Abstract

Objectives: Toll-like receptor 9 (TLR9), which recognizes hypomethylated DNA [cytosine-phosphate-guanine (CpG)], plays a role in the maintenance of serological memory and has been recently implicated in the pathogenesis of SLE. We previously reported that in vitro TLR9 triggers memory B-cell differentiation into antibody-producing cells, and that the MyD88-inhibitor ST2825 blocks TLR9-induced plasma cell (PC) generation. Here, we investigated whether memory B cells produce autoantibodies in SLE patients with active disease or in clinical remission, and whether ST2825 could inhibit PC generation in SLE patients. Methods: Peripheral blood mononuclear cells from 10 SLE patients in clinical remission and 2 with active SLE were cultured in the presence of CpG with or without ST2825. Phenotypical analysis of CpG-stimulated cells was performed by flow cytometry. Supernatants were collected to measure antibody production by ELISA and to detect autoantibodies by IF. Results: CpG-induced TLR9 stimulation caused autoantibody secretion in patients with active disease and in the majority of patients in clinical remission. Inhibition of MyD88 completely blocked the de novo generation of PCs and the secretion of autoantibodies. Conclusions: Autoreactive B cells persist in SLE patients during disease remission in the circulating B-cell memory pool. TLR9-dependent activation of memory B cells by pathogens could be one of the mechanisms triggering relapses in SLE. Compounds targeting the TLR/MyD88 pathway may be used as novel therapeutic tools to treat acute disease and to prevent relapses in SLE patients.

Original languageEnglish
Article numberkeq226
Pages (from-to)2281-2289
Number of pages9
JournalRheumatology
Volume49
Issue number12
DOIs
Publication statusPublished - Dec 2010

Keywords

  • Autoantibodies
  • Cell signalling
  • Cytosine-phosphate-guanine
  • Memory B cells
  • MyD88
  • SLE
  • ST2825
  • Toll-like receptor 9

ASJC Scopus subject areas

  • Rheumatology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Pharmacological inhibition of TLR9 activation blocks autoantibody production in human B cells from SLE patients'. Together they form a unique fingerprint.

  • Cite this

    Capolunghi, F., Rosado, M. M., Cascioli, S., Girolami, E., Bordasco, S., Vivarelli, M., Ruggiero, B., Cortis, E., Insalaco, A., Fantò, N., Gallo, G., Nucera, E., Loiarro, M., Sette, C., De santis, R., Carsetti, R., & Ruggiero, V. (2010). Pharmacological inhibition of TLR9 activation blocks autoantibody production in human B cells from SLE patients. Rheumatology, 49(12), 2281-2289. [keq226]. https://doi.org/10.1093/rheumatology/keq226